In a phase II study in 137 patients with advanced, inoperable HCC, of which 33 had their pre-treatment pERK levels evaluated, pre-treatment tumor pERK levels were correlated with the time to tumor progression. The gene discussed is EIF2AK3; the disease is hepatocellular carcinoma.